New developments in atherosclerosis: clinical potential of PCSK9 inhibition

References

• LalanneFLambertGAmarMJWild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cellsJ Lipid Res20054661312131915741654
   PubMed Web of Science ®Google Scholar
• PoirierSMayerGPouponVDissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular routeJ Biol Chem200928442288562886419635789
   PubMed Web of Science ®Google Scholar
• ZaidARoubtsovaAEssalmaniRProprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regenerationHepatology200848264665418666258
   PubMed Web of Science ®Google Scholar
• LipariMTLiWMoranPFurin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levelsJ Biol Chem201228752434824349123135270
   PubMed Web of Science ®Google Scholar
• EssalmaniRSusan-ResigaDChamberlandAIn vivo evidence that furin from hepatocytes inactivates PCSK9The J Biol Chem201128664257426321147780
   PubMed Web of Science ®Google Scholar
• BenjannetSRhaindsDHamelinJNassouryNSeidahNGThe pro-protein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modificationsJ Biol Chem200628141305613057216912035
   PubMed Web of Science ®Google Scholar
• HanBEachoPIKniermanMDIsolation and Characterization of the Circulating Truncated Form of PCSK9J Lipid Res20145571505151424776539
   PubMed Web of Science ®Google Scholar
• FanDYanceyPGQiuSSelf-association of human PCSK9 correlates with its LDLR-degrading activityBiochemistry20084761631163918197702
   PubMed Web of Science ®Google Scholar
• SunHSamarghandiAZhangNYaoZXiongMTengBBProprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptorArterioscler Thromb Vasc Biol20123271585159522580899
   PubMed Web of Science ®Google Scholar
• TavoriHFanDBlakemoreJLSerum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulationCirculation2013127242403241323690465
   PubMed Web of Science ®Google Scholar
• TavoriHGiunzioniILintonMFFazioSLoss of plasma proprotein convertase subtilisin/kexin 9 (PCSK9) after lipoprotein apheresisCirc Res2013113121290129524122718
   PubMed Web of Science ®Google Scholar
• ZhangDWLagaceTAGarutiRBinding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradationJ Biol Chem200728225186021861217452316
   PubMed Web of Science ®Google Scholar
• AbifadelMVarretMRabèsJPMutations in PCSK9 cause autosomal dominant hypercholesterolemiaNat Genet200334215415612730697
   PubMed Web of Science ®Google Scholar
• CohenJPertsemlidisAKotowskiIKGrahamRGarciaCKHobbsHHLow LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9Nat Genet200537216116515654334
   PubMed Web of Science ®Google Scholar
• CohenJCBoerwinkleEMosleyTHJrHobbsHHSequence variations in PCSK9, low LDL, and protection against coronary heart diseaseN Engl J Med2006354121264127216554528
   PubMed Web of Science ®Google Scholar
• CariouBOuguerramKZaïrYPCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemiaArterioscler Thromb Vasc Biol200929122191219719762784
   PubMed Web of Science ®Google Scholar
• ZhaoZTuakli-WosornuYLagaceTAMolecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygoteAm J Hum Genet200679351452316909389
   PubMed Web of Science ®Google Scholar
• HooperAJMaraisADTanyanyiwaDMBurnettJRThe C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African populationAtherosclerosis2007193244544816989838
   PubMed Web of Science ®Google Scholar
• KathiresanSMyocardial Infarction Genetics ConsortiumA PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarctionN Engl J Med2008358212299230018499582
   PubMed Web of Science ®Google Scholar
• StoneNJRobinsonJGLichtensteinAHAmerican College of Cardiology/American Heart Association Task Force on Practice Guidelines2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice GuidelinesCirculation201412925 Suppl 2S1S4524222016
   PubMed Web of Science ®Google Scholar
• MaronDJFazioSLintonMFCurrent perspectives on statinsCirculation2000101220721310637210
   PubMed Web of Science ®Google Scholar
• BrownMSDanaSEGoldsteinJLRegulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts by lipoproteinsProc Natl Acad Sci U S A1973707216221664352976
   PubMed Web of Science ®Google Scholar
• DubucGChamberlandAWassefHStatins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemiaArterioscler Thromb Vasc Biol20042481454145915178557
   PubMed Web of Science ®Google Scholar
• JeongHJLeeHSKimKSKimYKYoonDParkSWSterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2J Lipid Res200849239940917921436
   PubMed Web of Science ®Google Scholar
• FerenceBAMajeedFPenumetchaRFlackJMBrookRDEffect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial mendelian randomization studyJ Am Coll Cardiol201565151552156125770315
   PubMed Web of Science ®Google Scholar
• DiNicolantonioJJChatterjeeSLavieCJBangaloreSO’KeefeJHEzetimibe plus moderate-dose simvastatin after acute coronary syndrome: what are we IMPROVEing on?Am J Med20151288914e1914.e4.25731133
   PubMed Web of Science ®Google Scholar
• ShapiroMDFazioSTavoriHTargeting PCSK9 for therapeutic gainsCurr Atheroscler Rep201517449925712137
   PubMed Web of Science ®Google Scholar
• CiceroAFTartagniEErtekSEfficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin type 9: the available clinical evidenceExpert Opin Biol Ther201414686386824661068
   PubMed Web of Science ®Google Scholar
• DaduRTBallantyneCMLipid lowering with PCSK9 inhibitorsNat Rev Cardiol2014111056357524958078
   PubMed Web of Science ®Google Scholar
• CiceroAFTartagniEErtekSSafety and tolerability of injectable lipid-lowering drugs: a review of available clinical dataExpert Opin Drug Saf20141381023103024961142
   PubMed Web of Science ®Google Scholar
• SeidahNGAwanZChrétienMMbikayMPCSK9: a key modulator of cardiovascular healthCirc Res201411461022103624625727
   PubMed Web of Science ®Google Scholar
• SteinEARaalFReduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9Annu Rev Med20146541743124422577
   PubMed Web of Science ®Google Scholar
• TavoriHRashidSFazioSOn the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effectsAtherosclerosis2015238226427025544176
   PubMed Web of Science ®Google Scholar
• AndersonRGGoldsteinJLBrownMSLocalization of low density lipoprotein receptors on plasma membrane of normal human fibroblasts and their absence in cells from a familial hypercholesterolemia homozygoteProc Natl Acad Sci U S A197673724342438181751
   PubMed Web of Science ®Google Scholar
• AndersonRGBrownMSBeisiegelUGoldsteinJLSurface distribution and recycling of the low density lipoprotein receptor as visualized with antireceptor antibodiesJ Cell Biol19829335235316288727
   PubMed Web of Science ®Google Scholar
• AndersonRGBrownMSGoldsteinJLRole of the coated endocytic vesicle in the uptake of receptor-bound low density lipoprotein in human fibroblastsCell1977103351364191195
   PubMed Web of Science ®Google Scholar
• GoldsteinJLBrownMSThe LDL receptorArterioscler Thromb Vasc Biol200929443143819299327
   PubMed Web of Science ®Google Scholar
• FisherTSLo SurdoPPanditSEffects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulationJ Biol Chem200728228205022051217493938
   PubMed Web of Science ®Google Scholar
• CunninghamDDanleyDEGeogheganKFStructural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemiaNat Struct Mol Biol200714541341917435765
   PubMed Web of Science ®Google Scholar
• PearlsteinRAHuQYZhouJNew hypotheses about the structure-function of proprotein convertase subtilisin/kexin type 9: analysis of the epidermal growth factor-like repeat A docking site using WaterMapProteins201078122571258620589640
   PubMed Web of Science ®Google Scholar
• PiperDEJacksonSLiuQThe crystal structure of PCSK9: a regulator of plasma LDL-cholesterolStructure200715554555217502100
   PubMed Web of Science ®Google Scholar
• ZhangDWGarutiRTangWJCohenJCHobbsHHStructural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptorProc Natl Acad Sci U S A200810535130451305018753623
   PubMed Web of Science ®Google Scholar
• MousaviSABergeKEBergTLerenTPAffinity and kinetics of pro-protein convertase subtilisin/kexin type 9 binding to low-density lipoprotein receptors on HepG2 cellsFEBS J2011278162938295021692990
   PubMed Web of Science ®Google Scholar
• QianYWSchmidtRJZhangYSecreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosisJ Lipid Res20074871488149817449864
   PubMed Web of Science ®Google Scholar
• MaxwellKNBreslowJLAdenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotypeProc Natl Acad Sci U S A2004101187100710515118091
   PubMed Web of Science ®Google Scholar
• RaalFPanzVImmelmanAPilcherGElevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapyJ Am Heart Assoc201322e00002823537802
   PubMed Web of Science ®Google Scholar
• GrefhorstAMcNuttMCLagaceTAHortonJDPlasma PCSK9 preferentially reduces liver LDL receptors in miceJ Lipid Res20084961303131118354138
   PubMed Web of Science ®Google Scholar
• DeVayRMSheltonDLLiangHCharacterization of proprotein convertase subtilisin/kexin type 9 (PCSK9) trafficking reveals a novel lysosomal targeting mechanism via amyloid precursor-like protein 2 (APLP2)J Biol Chem201328815108051081823430252
   PubMed Web of Science ®Google Scholar
• KosenkoTGolderMLeblondGWengWLagaceTALow-density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated LDL receptor degradationJ Biol Chem2013288128279828823400816
   PubMed Web of Science ®Google Scholar
• RomagnuoloRScipioneCABoffaMBMarcovinaSMSeidahNGKoschinskyMLLipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptorJ Biol Chem201529018116491166225778403
   PubMed Web of Science ®Google Scholar
• WangWWangEQBalthasarJPMonoclonal antibody pharmacokinetics and pharmacodynamicsClin Pharmacol Ther200884554855818784655
   PubMed Web of Science ®Google Scholar
• SupersaxoAHeinWRSteffenHEffect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administrationPharm Res1990721671692137911
   PubMed Web of Science ®Google Scholar
• LoboEDHansenRJBalthasarJPAntibody pharmacokinetics and pharmacodynamicsJ Pharm Sci200493112645266815389672
   PubMed Web of Science ®Google Scholar
• DostalekMGardnerIGurbaxaniBMRoseRHChettyMPharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodiesClin Pharmacokinet20135228312423299465
   PubMed Web of Science ®Google Scholar
• WaldmannTAStroberWMetabolism of immunoglobulinsProg Allergy19691311104186070
   PubMedGoogle Scholar
• ComberPGGomezFRossmanMDSchreiberADReceptors for the Fc portion of immunoglobulin G (Fc gamma R) on human monocytes and macrophagesProg Clin Biol Res19892972732852531420
   PubMedGoogle Scholar
• KawaguchiYKonoKMimuraKTargeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinomaBr J Cancer200797449450117622245
   PubMed Web of Science ®Google Scholar
• FoltzINKarowMWassermanSMEvolution and emergence of therapeutic monoclonal antibodies: what cardiologists need to knowCirculation2013127222222223023733968
   PubMed Web of Science ®Google Scholar
• PressOWHansenJAFarrAMartinPJEndocytosis and degradation of murine anti-human CD3 monoclonal antibodies by normal and malignant T-lymphocytesCancer Res1988488224922572964899
   PubMed Web of Science ®Google Scholar
• KeizerRJHuitemaADSchellensJHBeijnenJHClinical pharmacokinetics of therapeutic monoclonal antibodiesClin Pharmacokinet201049849350720608753
   PubMed Web of Science ®Google Scholar
• JunghansRPAndersonCLThe protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptorProc Natl Acad Sci U S A19969311551255168643606
   PubMed Web of Science ®Google Scholar
• LiangHChaparro-RiggersJStropPProprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primatesJ Pharmacol Exp Ther2012340222823622019884
   PubMed Web of Science ®Google Scholar
• ChanJCPiperDECaoQA proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primatesProc Natl Acad Sci U S A2009106249820982519443683
   PubMed Web of Science ®Google Scholar
• Chaparro-RiggersJLiangHDeVayRMIncreasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9J Biol Chem201228714110901109722294692
   PubMed Web of Science ®Google Scholar
• IgawaTIshiiSTachibanaTAntibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralizationNat Biotechnol201028111203120720953198
   PubMed Web of Science ®Google Scholar
• HenneKRAsonBHowardMAnti-PCSK9 antibody pharmacokinetics and low-density lipoprotein-cholesterol pharmacodynamics in nonhuman primates are antigen affinity-dependent and exhibit limited sensitivity to neonatal Fc receptor-binding enhancementJ Pharmacol Exp Ther2015353111913125653417
   PubMed Web of Science ®Google Scholar
• LunvenCPaehlerTPoitiersFA randomized study of the relative pharmacokinetics, pharmacodynamics, and safety of alirocumab, a fully human monoclonal antibody to PCSK9, after single subcutaneous administration at three different injection sites in healthy subjectsCardiovasc Ther201432629730125256660
   PubMed Web of Science ®Google Scholar
• SteinEAMellisSYancopoulosGDEffect of a monoclonal antibody to PCSK9 on LDL cholesterolN Engl J Med2012366121108111822435370
   PubMed Web of Science ®Google Scholar
• HuijgenRFouchierSWDenounMPlasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemiaJ Lipid Res201253597998322375030
   PubMed Web of Science ®Google Scholar
• WaltonTANishtarSLumbPJPro-protein convertase subtilisin/kexin 9 concentrations correlate with coronary artery disease atheroma burden in a Pakistani cohort with chronic chest painInt J Clin Pract201569773874225707773
   PubMed Web of Science ®Google Scholar
• ChengJMOemrawsinghRGarcia-GraciaHSerum proprotein convertase subtilisin/kexin type 9 level is associated with coronary plaque inflammation and cardiovascular outcome independent from serum LDL levelAbstract presented at: American Heart Association Scientific Sessions 2014November 7–11 2014Orlando, FL USA Abstract 130A16101
   Google Scholar
• KuhnastSvan der HoornJWPietermanEJAlirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statinJ Lipid Res201455102103211225139399
   PubMed Web of Science ®Google Scholar
• GiunzioniITavoriHCovarrubiasRMajorALintonMFFazioSMacrophage expression of Pcsk9 influences atherosclerosis developmentAHA Sci Session20131282 SupplA19083
   Google Scholar
• MarksDThorogoodMNeilHAHumphriesSEA review on the diagnosis, natural history, and treatment of familial hypercholesterolaemiaAtherosclerosis2003168111412732381
   PubMed Web of Science ®Google Scholar
• RaalFJHonarpourNBlomDJTESLA InvestigatorsInhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trialLancet2015385996534135025282520
   PubMed Web of Science ®Google Scholar
• SteinEAHonarpourNWassermanSMXuFScottRRaalFJEffect of the PCSK9 Monoclonal Antibody, AMG 145, in Homozygous Familial HypercholesterolemiaCirculation2013128192113212024014831
   PubMed Web of Science ®Google Scholar
• LambertGPetridesFChatelaisMElevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defectsJ Am Coll Cardiol201463222365237324632287
   PubMed Web of Science ®Google Scholar
• LambertGChatelaisMPetridesFNormalization of low-density lipoprotein receptor expression in receptor defective homozygous familial hypercholesterolemia by inhibition of PCSK9 with alirocumabJ Am Coll Cardiol201464212299230025456764
   PubMed Web of Science ®Google Scholar
• SabatineMSGiuglianoRPWiviottSDOpen-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular eventsN Engl J Med2015372161500150925773607
   PubMed Web of Science ®Google Scholar
• RobinsonJGFarnierMKrempfMODYSSEY LONG TERM InvestigatorsEfficacy and safety of alirocumab in reducing lipids and cardiovascular eventsN Engl J Med2015372161489149925773378
   PubMed Web of Science ®Google Scholar
• CVS health raises concerns about the potential impact of new class of cholesterol drugs on the health care system [webpage on the Internet]Woonsocket, RICVS Health Available from: http://www.cvshealth.com/newsroom/press-releases/cvs-health-raises-concerns-about-potential-impact-new-class-cholesterolAccessed July 2, 2015
   Google Scholar